I placebokontrollerede forsøg med patienter med hypertension afveg den overordnede forekomst af bivirkninger med irbesartan (56, 2%) ikke fra placebogruppernes (56, 5%).
In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%).